Pliant Therapeutics, Inc.

NasdaqGS:PLRX 株式レポート

時価総額:US$649.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Pliant Therapeutics 将来の成長

Future 基準チェック /26

Pliant Therapeuticsの収益は年間2.5%で減少すると予測されていますが、年間収益は年間70.9%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-70.8% 5.8%なると予測されています。

主要情報

-2.3%

収益成長率

6.0%

EPS成長率

Pharmaceuticals 収益成長27.6%
収益成長率71.5%
将来の株主資本利益率-70.8%
アナリストカバレッジ

Good

最終更新日21 Jun 2024

今後の成長に関する最新情報

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

業績と収益の成長予測

NasdaqGS:PLRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20264-275-235-21910
12/31/20256-246-199-19612
12/31/20242-208-142-16012
3/31/20240-171-119-116N/A
12/31/20232-161-117-116N/A
9/30/20234-155-124-122N/A
6/30/20235-144-106-105N/A
3/31/202310-133-106-104N/A
12/31/202210-123-96-95N/A
9/30/202210-113-85-83N/A
6/30/202210-109-89-87N/A
3/31/20227-103-85-82N/A
12/31/20218-97-77-75N/A
9/30/202110-92-74-72N/A
6/30/202113-81-67-65N/A
3/31/202115-75-40-38N/A
12/31/202042-42-39-37N/A
9/30/202094181516N/A
6/30/202090191617N/A
3/31/20208620-6-5N/A
12/31/201957-7-4-3N/A
3/31/2019N/A-43-33-32N/A
12/31/2018N/A-35-31-28N/A

アナリストによる今後の成長予測

収入対貯蓄率: PLRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PLRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PLRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PLRXの収益 ( 70.9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: PLRXの収益 ( 70.9% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: PLRX 3 年以内に赤字になると予測されています。


成長企業の発掘